🏥隨著當今各種新藥百花齊放，醫療器材的創新進展也是醫療產業中不可忽視的一塊。從更精準快速的診斷分析，到各種影像技術，或是日新月異的醫材器械都提供了醫師以及病人更多元的治療手段。
🏥不過到底什麼才算是醫療器材？ 醫療器材的開發與規範跟新藥研發有哪些相似之處？BTBA一月月會邀請了在醫療器材產業界有多年經驗的Dr. John Perng以及Dr. Philip Chiu。他們將解答大家的各種疑問，以及洞悉醫療器材產業的動向與未來發展。
🚑Amid the rapid growth of new drugs today, innovation in medical devices is also an indispensable aspect of the healthcare industry. With more precise and expedited diagnostic analyses, various imaging technologies, and the continually advancing landscape of medical devices and equipment, nowadays, physicians and patients can benefit from more diverse treatment options.
🚑However, what defines a medical device? How does its development and regulation compare to the research and development of new pharmaceuticals?
🚑In the upcoming January BTBA panel discussion, we are pleased to invite Dr. John Perng and Dr. Philip Chiu, both with extensive experience in the medical device industry. They will address various questions about medical devices and provide insights into the trends and future developments of the medical device industry.
❗在此報名 Sign up here: https://forms.gle/6kJxPjt3PwzsvuUC7
🗣️本實體活動全程以英文進行 The event will be in English; In-person only
🕘 Time: 2024-01-21 (Sun)
📍 Place: Lehman Hall 201 at Harvard University, MA 02138 (near MBTA Harvard Station)
Co-Founder, CMO, Galliomni Inc
John has 15 years of experience in the medical device, life science and healthcare industry. John started his career as a senior scientist at Siemens Healthineers and developed point-of-care clinical diagnostics in ICU and ER settings. Then he received an MBA from IMD in Switzerland and became a global product manager at Leica Microsystems. He was responsible for the surgical imaging portfolio and grew the medical business from $50M to $80M in 4 years. He led multiple product development projects from concept to commercialization, including extensive experience in regulatory clearance from FDA (US), CE mark (Europe), Japan, NMPA (China), and INMETRO (Brazil). During his tenure at Leica, he turned around a failed startup acquisition into a center of excellence and built international team across US, Europe, India, and Singapore. In 2021, John became the Head of Digital Solutions at Lifescan and was responsible for developing consumer-driven mobile apps and data strategy for the Continuous Glucose Monitoring business. John is currently a startup co-founder (Galliomni) and building enterprise data platforms for the life science industry.
John holds a PhD in Bioengineering and MS in Electrical Engineering from Georgia Institute of Technology, BS in Electrical Engineering from UC Berkeley, and MBA from IMD.
Distinguished Cardiovascular R&D engineer, Abbott Vascular
Philip Chiu, Ph.D. is a distinguished Cardiovascular R&D engineer with a robust background in biomedical engineering. Holding a Ph.D. in Biomedical Engineering from Stony Brook University since 2018, he has been at the forefront of cutting-edge research and development within the cardiovascular domain. Currently serving as a staff R&D engineer at Abbott Vascular, Philip specializes in advanced technology development, with a primary focus on the intricate field of intravascular coronary imaging applications. Over the past decade, Philip has accumulated a wealth of research experiences, notably in the realm of implantable cardiovascular devices. His expertise spans Ventricular Assist Devices (VADs), Total Artificial Hearts (TAHs), and Prosthetic Aortic Valves. Philip’s comprehensive skills and knowledge are evident in his proficiency in designing and conducting numerical simulations and analyses, coupled with extensive hands-on in vitro experiences.
Philip’s commitment to advancing cardiovascular science is underscored by his outstanding records in peer-reviewed publications. With a keen eye for innovation, he has contributed to over 10 invention disclosures and patents filed, showcasing his dedication to pushing the boundaries of what is possible in the field. In his role at Abbott Vascular, Philip continues to be a driving force in shaping the future of cardiovascular technology. With a proven track record of excellence, he remains open to embracing new challenges that allow him to further apply his expertise and contribute to the forefront of cardiovascular research and development. Philip’s passion for innovation and commitment to advancing healthcare technologies position him as a valuable asset in the ever-evolving landscape of biomedical engineering.
Scientist, Bristol Myers Squibb
Tsung-Lin is a Scientist at Bristol Myers Squibb (BMS), where he contributes his expertise to the Biologics Development group. Specializing in biologics purification processes across various scales, he plays a crucial role in advancing manufacturing capabilities. Prior to joining BMS, he earned his Ph.D. in Chemical Engineering from Carnegie Mellon University, where his research focused on colloidal and interfacial phenomena.